TXNRD2 Antibody

What is TXNRD2 and what is its role in cellular function?

TXNRD2 (Thioredoxin Reductase 2) is a mitochondrial selenoprotein that plays a critical role in maintaining redox homeostasis. It functions as a component of the thioredoxin system along with NADPH and thioredoxin. TXNRD2 is involved in:

• Control of reactive oxygen species (ROS) levels

• Regulation of mitochondrial redox homeostasis

• Maintaining thioredoxin in a reduced state

• Prevention of oxidative stress

• Potential role in redox-regulated cell signaling

TXNRD2 is typically detected at approximately 54-56 kDa on Western blots:

• Calculated molecular weight: 56 kDa (524 amino acids)

• Observed molecular weight: 54 kDa

This information is important for confirming correct band identification in Western blot experiments .

How do you optimize TXNRD2 antibody dilution for Western blot experiments?

Optimizing antibody dilution is crucial for obtaining specific signals while minimizing background:

• Starting dilution ranges:

  • Western Blot: 1:1000-1:6000

  • Abcam's EPR12480 antibody: 1:1000

  • Sigma-Aldrich rabbit polyclonal: Typically used at 1:1000-1:2000

• Optimization protocol:

  • Begin with the manufacturer's recommended dilution

  • Test multiple dilutions in a dilution series

  • Include positive controls (HepG2, HeLa, MCF-7 cells, or rat liver tissue)

  • Include negative controls (TXNRD2 knockout lysates if available)

  • Evaluate signal-to-noise ratio at each dilution

  • Select the dilution that provides optimal specific signal with minimal background

• Validation approach:

  • Confirm specificity using TXNRD2 knockout cell lysates (e.g., TXNRD2 knockout HEK-293T cell lysate)

  • Include loading controls (e.g., GAPDH)

What are the recommended protocols for using TXNRD2 antibodies in immunohistochemistry?

For optimal immunohistochemistry results with TXNRD2 antibodies:

• Sample preparation:

  • Formalin-fixed, paraffin-embedded (FFPE) tissue sections

  • For frozen sections, fixation with 2% paraformaldehyde may be used

• Antigen retrieval:

  • Primary method: TE buffer pH 9.0

  • Alternative method: Citrate buffer pH 6.0

• Antibody dilution:

  • IHC: 1:50-1:500

  • For NBP2-20768: 1:500 dilution has been validated on paraffin-embedded xenograft samples

• Detection systems:

  • Secondary antibody conjugated to HRP for chromogenic detection

  • Fluorescent secondary antibodies for immunofluorescence

• Controls:

  • Positive tissue controls (human liver tissue has been validated)

  • Negative controls (primary antibody omission)

  • Isotype controls to assess non-specific binding

How can TXNRD2 antibodies be used to study mitochondrial redox homeostasis?

TXNRD2 antibodies can be instrumental in investigating mitochondrial redox status:

• Monitoring TXNRD2 protein levels:

  • Western blot analysis of TXNRD2 expression under oxidative stress conditions

  • Quantification of changes in TXNRD2 protein levels in response to redox modulators

• Assessing thioredoxin system redox status:

  • Examining monomer (reduced/active) to dimer (oxidized/inactive) ratio of peroxiredoxins (PRDXs)

  • PRDX3 monomer/dimer analysis by non-reducing SDS-PAGE to monitor mitochondrial thioredoxin system activity

• Protein-protein interaction studies:

  • Co-immunoprecipitation to assess TXNRD2-TXN2 interactions under various redox conditions

  • Changes in these interactions can indicate alterations in redox homeostasis (e.g., erastin treatment disrupts TXNRD2-TXN2 interaction)

• Subcellular localization:

  • Immunofluorescence to confirm mitochondrial localization of TXNRD2

  • Co-localization with mitochondrial markers

What methodological approaches can be used to study TXNRD2 CoAlation and its impact on enzyme activity?

CoAlation (modification by Coenzyme A) of TXNRD2 is an emerging area of research with significant implications for enzyme regulation:

• Detecting TXNRD2 CoAlation:

  • Purify V5-tagged TXNRD2 from cells overexpressing TXNRD2-V5

  • Incubate with oxidized CoA in vitro

  • Separate using native gel electrophoresis and blot with anti-CoA antibody

  • Non-reducing gel electrophoresis followed by anti-CoA antibody staining

• Assessing enzymatic activity changes:

  • In vitro thioredoxin reductase assay with CoAlated and non-CoAlated TXNRD2

  • Use thioredoxin reductase inhibitors (e.g., auranofin) as controls

  • Compare enzymatic activity before and after CoAlation

• Identifying CoAlation sites:

  • Bottom-up mass spectrometry on oxidized CoA-treated tryptic digested TXNRD2

  • Look for mass modifications corresponding to fragmented CoA (+338.07 Da)

  • Site-directed mutagenesis of identified CoAlation sites (e.g., Cys-483 to alanine)

  • Functional validation of mutants to confirm the importance of specific residues

• Investigating physiological regulators of CoAlation:

  • Modulate cystine/cysteine availability using erastin

  • Manipulate CoA levels through knockdown of CoA synthase (COASY)

  • Combine with CoA supplementation to rescue effects

  • Assess impact on TXNRD2 CoAlation and activity

How do you design experiments to investigate the relationship between TXNRD2 and hypoxia-inducible factor signaling?

TXNRD2 has been linked to hypoxia-inducible factor-1α (HIF-1α) signaling, providing important insights into tumor biology:

• Genetic manipulation approaches:

  • Generate TXNRD2 knockout or knockdown cell lines using CRISPR/Cas9 or shRNA

  • Create rescue models with wild-type and mutant TXNRD2

  • Compare HIF-1α signaling between control and manipulated cells

• Analysis of HIF-1α pathway components:

  • Assess PHD2 accumulation by Western blot

  • Measure HIF-1α degradation kinetics

  • Quantify VEGF levels by ELISA or qRT-PCR

  • Evaluate JNK activation as a molecular link between TXNRD2 loss and PHD2 upregulation

• Tumor growth and angiogenesis studies:

  • Xenograft models with TXNRD2-deficient tumor cells

  • Measure tumor growth rate

  • Assess tumor vascularization by immunohistochemistry for CD31

  • Compare VEGF expression in tumors

• Combined targeting approach:

  • Simultaneous inhibition of both mitochondrial thioredoxin and glutathione systems

  • Therapeutic evaluations in preclinical models

  • Monitoring tumor growth and redox status

What controls should be included when using TXNRD2 antibodies in experimental settings?

Rigorous controls are essential for ensuring reliability and reproducibility in TXNRD2 antibody-based experiments:

• Positive controls:

  • Cell lines with confirmed TXNRD2 expression: HepG2, HeLa, MCF-7

  • Tissue samples: Human or rat liver tissue

  • Overexpression systems with tagged TXNRD2

• Negative controls:

  • TXNRD2 knockout cell lines (e.g., Human TXNRD2 knockout HEK-293T cells)

  • TXNRD2 knockout cell lysates for Western blot validation

  • Primary antibody omission in immunohistochemistry

• Specificity validation:

  • Peptide competition assays

  • Multiple antibodies targeting different epitopes

  • siRNA knockdown to confirm signal reduction

  • Nonreducing vs. reducing conditions to assess redox-sensitive epitopes

• Technical controls:

  • Loading controls for Western blots (e.g., GAPDH)

  • Isotype controls for immunohistochemistry

  • Subcellular fractionation controls for mitochondrial localization

• Redox state controls:

  • DTT treatment to disrupt disulfide bonds and CoAlation

  • Beta-mercaptoethanol to remove CoA modifications

  • Oxidizing and reducing conditions to confirm redox sensitivity

How can researchers study the involvement of TXNRD2 in human pathological conditions?

TXNRD2 variants have been implicated in several human conditions, providing opportunities to study its role in pathophysiology:

• Genetic analysis approaches:

  • Whole-genome or whole-exome sequencing to identify TXNRD2 variants

  • Genotype-phenotype correlation studies

  • Segregation analysis in families with suspected TXNRD2-related disorders

• Functional characterization of patient-derived samples:

  • Protein expression analysis by immunoblotting with anti-TXNRD2 antibodies

  • mRNA expression quantification by RT-PCR

  • Measurement of redox parameters (e.g., glutathione:oxidized glutathione ratio)

• Disease model systems:

  • Patient-derived cells

  • CRISPR/Cas9-engineered cell lines with specific TXNRD2 variants

  • Animal models with corresponding mutations

• Clinical correlation studies:

  • TXNRD2 variants in familial glucocorticoid deficiency

  • Association with micropenis and atypical genitalia

  • Comparison with knockout mouse phenotypes (embryonic lethality due to hematopoietic and cardiac defects)